Summary p53 messenger RNA expression was examined using a cDNA probe in 76 fresh primary breast tumour specimens, 15 of which came from patients treated with taxoxifen prior to surgery. A 2.8 kb mRNA for p53 was expressed in 43 of the 76 specimens. In 19 tumours the levels were similar to those seen in non-malignant (reduction mammoplasty) breast tissue, but in 24 tumours over-expression of mRNA for p53, approaching that seen in three breast cancer cell lines, was found. The cell lines MCF-7, T47D and MDA-MB-231 expressed three p53 mRNA species of about 2.8 kb and a fourth of 1.6 kb. Increased mRNA expression for p53 correlated (P <0.05) with loss of genetic material from the short arm of chromosome 17 as demonstrated by allele loss with the VNTR probe YNZ 22.1. There was also statistically significant correlation between increased p53 mRNA expression and low oestrogen receptor protein content in the tumours (P <0.05), but not with other clinical parameters. The findings support the view that p53 is involved in breast tumour biology, and suggest that its role may be complex.
p53 is a 53 kDa phosphoprotein with a short half-life (5-45 min) (Reich & Levine, 1984; Halevy et al., 1988) . The role of p53 protein remains obscure although the p53 gene has the structural features of a 'housekeeping' gene, including absence of a TATA box (Reynolds et al., 1984; BienzTadmor et al., 1985) . p53 may modulate transcriptional activation by binding to DNA in a similar way to the myc protein (Donner et al., 1982) , allowing cells to progress from a growth arrested state to an actively dividing state or to bypass the need for platelet derived growth factor in the induction of competence (Oren, 1986) .
Despite persuasive evidence for its role as an oncogene (Eliyahu et al., 1984 (Eliyahu et al., , 1985 Parada et al., 1984; Editorial, 1988; Oren, 1986) there is also reason to believe that p53 can act as a tumour suppressor gene (Green, 1989; Wang et al., 1989) . This paradox may be resolved if rearrangements of the p53 DNA alter the structure, expression (Masuda et al., 1987) or stability (Jenkins et al., 1985) of the 53 kDa protein product and if the function of a mutated p53 product differs from that of the normal gene (Green, 1989) . The p53 gene maps to the 13.1 region of the short arm of chromosome 17 (Miller et al., 1986) . One previous study (Masuda et al., 1987) did not find detectable changes in the p53 gene in breast cancer. However, using the YNZ 22.1 probe , which also maps near the tip of 17p at 13.3, Mackay et al. (1988) found most patients had two alleles in their constitutional (blood) DNA and 61% of these informative patients had demonstrable loss of one allele (loss of heterozygosity) in the tumour DNA. p53 mRNA and p53 protein levels may (Reich et al., 1983) or may not (Richon et al., 1989) correspond, since regulation of p53 expression can occur at the level of mRNA abundance or of p53 protein stability, depending on the system under study (Rovinski et al., 1987) .
While previous work on human breast cancer has examined p53 protein expression (Cattoretti et al., 1988) or chromosome 17p allelic loss (Mackay et al., 1988; Devilee et al., 1989) , no previous study has attempted to (Soule et al., 1973) , MDA-MB-231 (Cailleau et al., 1974) and T-47D (Keydar et al., 1979) were cultured and maintained under mycoplasmafree (Barile, 1973) standard conditions. They were harvested in the logarithmic phase of growth and the RNA was extracted for comparison with that from the tumours.
Ribonucleic acid extraction From frozen tumour, total ribonucleic acid (RNA) was extracted using a modification of the method of Auffrey and Rougeon (1980 Southern, 1975) . The filter was rinsed in 2 x SSC and air-dried, and the RNA was covalently fixed to the membrane using a UV transilluminator. The filter and remaining gel were photographed to check for adequate transfer of the RNA. ethanol in the presence of salt (Steel, 1984) . Precipitated DNA was spooled from the alcohol, air-dried and redissolved in Tris/EDTA buffer, and the concentration and purity of the DNA were assessed using spectrophotometry at 260 nm and 280 nm. DNA was extracted from 20 ml venous blood in a similar way, but with an additional protein extraction and precipitation step prior to RNase treatment.
DNA (5gg) from each patient's blood and tumour was digested using a bacterial endonuclease (for example, Tab I), the samples were separated electrophoretically alongside digested lambda markers on a 0.8% agarose gel, the DNA fragments transferred to a hybond-N membrane (Amersham, UK) using the Southern blot technique (Southern, 1975) and the DNA was fixed to the membrane with ultraviolet light and baking at 80°C for 2 h.
The membrane was incubated in hybridisation buffer (5 x Denhart's, 5 x SSC, 0.1% SDS, 10% dextran sulphate) to which Io1 c.p.m. ml-I' 32P-CTP-labelled YNZ 22.1 insert was added and allowed to hybridise for 24h.
Excess probe was washed from the membrane using successive washes of 0.1% SDS and I x SSC and the DNA fragments were detected by autoradiography at -70°C to pre-flashed Kodak XAR film.
Oestrogen receptors
The oestrogen receptor content was measured using the Enzyme Immunoassay (EIA; kit from Abbott Laboratories, North Chicago, IL, USA) and expressed in fmol per mg protein for both the tumours and the cell lines. Oestrogen receptor protein concentrations of 20 fmol mg-' protein or greater were considered to be 'significant' (moderate to rich).
Probe hybridisation Filters were pre-hybridised in 7% SDS, 0.5 M disodium hydrogen phosphate (pH 7.2) and I mM EDTA pH 7.0 (method modified from Church & Gilbert, 1984) for 30 min at 65°C. To this was added 32P-cytidine triphosphate (CTP) labelled cDNA probe, with specific activity to io1 c.p.m. ml-' using a random prime DNA-labelling system (Boehringer Mannheim, FRG). 12P-CTP incorporated probe was separated from unincorporated radionucleotide using a Sephadex column (Nick column, Pharmacia, UK) and denatured before addition to the hybridisation solution.
To detect the p53 mRNA, the 2.1 kb cDNA clone php53Bam of p53 protein mRNA cut from pBR322 (ZakutHouri et al., 1985) was used. Following 24 h hybridisation, filters were washed to remove non-specifically attached probe in two changes of 0.1% SDS 10mM disodium hydrogen phosphate wash buffer at 65°C with agitation. The filters were blotted dry, wrapped in clingfilm and exposed to preflashed Kodak XAR film at -70°C for up to 14 days.
The extent of hybridisation of radiolabelled probe to the mRNA species was determined from densitometry (using a laser densitometer constructed by the Medical Research Council Human Genetics Unit) and expressed with respect to hybridisation to the actin probe. The size of each mRNA species was calculated from the position of ribosomal RNA markers.
The filters were stripped of residual probe by washing at 80'C for 60 min in 0.1% SDS and the filter was checked by autoradiography. As a standard probe, the Pst I insert cDNA of plasmid 91, detecting mouse a-actin mRNAspecific sequences (Minty et al., 1981) was then hybridised and washed under the above conditions to quantify accurately the mRNA in each total RNA sample loaded.
DNA extraction DNA was extracted from frozen tissue by disrupting finely chopped tissue in lysis buffer containing 1% SDS. Impurities were removed by using RNase and proteinase K, then phenol and chloroform, and the DNA was precipitated using Results A 2.8 kb p53 mRNA was detected in 43 of the 76 tumour specimens (57%), in all three breast cancer cell lines and in six of the 10 reduction mammoplasty specimens (Figure 1 ). Low levels of this p53 mRNA (comparable to those found in the six positive mammoplasty specimens) were also detected in normal human tonsil, uterus and ovarian tissue (data not shown). There were quantitative differences between the tumour specimens and qualitative differences between the tumours and the cell lines. Thirty-three of the 76 patients had no detectable p53 mRNA in their tumour tissue and 19 patients had detectable p53 mRNA of 2.8 kb similar to quantity to the reduction mammoplasty specimens that gave a positive signal. Twenty-four patients had increased levels of the 2.8 kb p53 mRNA approaching those found in the cell lines. The three breast cancer cell lines each yielded four p53 mRNA species. Three closely related species were of approximately 2.8 kb, with differences between cell lines in the amounts of mRNA for each of these species. A fourth (1.6 kb) p53 mRNA was strongly expressed in all three lines.
Cell line
There was a significant tendency for increased tumour p53 mRNA expression to be associated with clinically insignificant levels of oestrogen receptor protein (P = 0.049, x2 test; Table I (Figure 2) .
Loss of genetic material from the tip of the short arm of chromosome 17, as determined by loss of heterozygosity using the YNZ 22.1 probe, was significantly correlated with increased p53 mRNA expression (Table II, P = 0.04, x2 test).
Allelic loss was also correlated with low levels of oestrogen receptor protein (P = 0.024, Fisher's exact test). When the present data are combined with those from our earlier series (Mackay et al., 1988 ) the association becomes highly significant (Table III , P <0.01). 
Discussion
This study has examined p53 mRNA expression and loss of genetic material from the short arm of chromosome 17 in 76 patients. A 2.8 kb mRNA for p53 was detected in 43 of the 76 breast cancer specimens. This corresponds to the mRNA for p53 identified in previous studies of human tissue (Harlow et al., 1985; Baker et al., 1989) . The quantitative difference between tumours in p53 mRNA expression raises the possibility that the p53 gene may fulfil different functions in the patients with no detectable mRNA by comparison with those in whom there was normal or increased expression. In those tumours where no p53 mRNA was detected, this may reflect deficiency of normal (unmutated) p53 and hence a reduced tumour suppressor function. Deletion of one copy of the p53 gene is compatible with increased function of the other (abnormal) gene. Thus, where there is normal or increased p53 mRNA expression, this may be of a mutated form (for example a point mutation), which therefore acts as an oncogene, promoting carcinogenesis. Alternatively, loss of one allele may confer a minor growth advantage, with subsequent mutation of the remaining p53 required to initiate or promote carcinogenesis. If mutation were to occur first, loss of the normal allele may be required to allow effective expression of the mutant p53, by analogy with co-transfection studies of normal and mutated H-ras (Spandidos & Wilkie, 1988) . The step between normal and mutated p53 cannot readily be established using the Northern blot technique, although future use of the polymerase chain reaction (Saiki et al., 1985) should clarify the situation.
The qualitative differences between the tumours and cell lines may reflect reading frame differences (likely to give rise to the 1.6 kb mRNA) or splicing, or even different adenylated tail lengths resulting in the three messages of about 2.8 kb in size. However, when MCF-7 cells are grown as xenografts in immunosuppressed mice, only a single 2.8 kb p53 mRNA species and no 1.6 kb mRNA is detected in the tumour tissue. This finding is independent of the rate of tumour growth (A.M. Thompson, manuscript in preparation). A single p53 mRNA species of 1.8 kb has been noted previously in NIH3T3 cells (Reich et al., 1983; Reich & Levine, 1984) and this mRNA may correspond to the nuclear mRNA regulating translation detected by Khochbin and Lawrence (1988 This study confirms that the loss of one YNZ 22.1 allele from the short arm of chromosome 17 occurs in over half the breast tumours studied (Mackay et al., 1988 , Devilee et al., 1989 and establishes for the first time that this allele loss correlates with clinically insignificant levels of oestrogen receptor protein. The tip of the short arm of chromosome 17 is thus of importance in breast as well as in colon cancer (Lothe et al., 1988; Vogelstein et al., 1989) .
Although of all the highly informative probes available for this study, YNZ 22.1, located at 17p 13.3, was the closest to the p53 (17p 13.1) locus, it is still several megabases telomeric to the p53 gene. The correlation between loss of heterozygosity for YNZ 22.1 and p53 mRNA expression provides evidence that there may be some link between a putative gene conferring increased susceptibility to cancer (Mackay et al., 1988) and the oncogene or tumour suppressor gene function of p53.
Eleven of the 76 patients had tumours showing loss of heterozygosity for YNZ 22.1, increased expression of p53 mRNA and low levels of oestrogen receptor protein. With just 12 months mean follow-up, two of these patients have already relapsed with metastatic disease. Continued follow-up of the whole cohort will establish the prognostic significance of the present findings.
The observation that, in almost a third of tumours, p53 mRNA levels were elevated while, in a comparable proportion, the message was not detectable, supports the view that p53 is involved in breast tumour biology. Whether this is as an oncogene or as a tumour suppressor gene (possibly as either, depending on the individual tumour) remains to be seen. The advent of highly polymorphic probes for the p53 gene and the application of more recent technology, such as the polymerase chain reaction, should resolve these issues.
